MOJ eISSN: 2374-6920 MOJPB

Proteomics & Bioinformatics
Volume 1 Issue 2

Proteomics and bioinformatics and the future of personalized medicine
Isabelle Mercier
Department of Pharmaceutical Sciences, University of the Sciences, USA
Received: June 17, 2014 | Published: June 18, 2014

Correspondence: Isabelle Mercier, Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy (PCP), University of the Sciences, 600 S. 43rd St.PTC Building room # 238, Philadelphia, PA 19104, USA, Email

Citation: Mercier I. Proteomics and bioinformatics and the future of personalized medicine. MOJ Proteomics Bioinform. 2014;1(2):31. DOI: 10.15406/mojpb.2014.01.00008


MedCrave Online Journal for Proteomics and Bioinformatics (MOJPB) is a scientific journal that will gain increasing recognition in upcoming years. I am very happy to become a member of the team as an associate editor. I believe the visibility of the journal will be enhanced over the next five years, allowing the recruitment of innovative studies that will allow a steep rise in its impact factors.

A key objective of personalized medicine is to translate proteomics and bioinformatics information into clinical practice and health care delivery to patients. Thus, MOJPB journal has an ideal format to recruit ground-breaking articles that relate to translational medicine. Importantly, these types of manuscripts bring together teams of basic scientists and clinicians. MOJPB will contribute to integrate these important fields thus allowing better customized patient care. MOJPB is the perfect vessel to deliver such translational articles to the scientific community and I predict this will continue to contribute to its rapid growth within the next few years.

In summary, proteomics and bioinformatics are the future of personalized medicine. Having translational publications in MOJPB will contribute to the dissemination of new laboratory diagnostics leading to improved patient health. Very few currently available online journals have such a rare opportunity to contribute directly to patients care through the publications of clinically relevant studies that have translational value. It is thus my pleasure to be part of the journal to continue its journey to deliver personalized medicine care to patients and to guide them towards informed treatment decisions.



Conflict of interest

The author declares no conflict of interest.

©2014 Mercier. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.
© 2014-2019 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy